Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract
Interventions: DRUG: Pembrolizumab|BIOLOGICAL: Clostridium Novyi-NT|DRUG: Doxycycline
Sponsor: M.D. Anderson Cancer Center
Collaborators: BioMed Valley Discoveries, Inc|Merck Sharp & Dohme LLC